default author photo

Rachelle Buchannan

University of Saskatchewan - Vaccine and Infectious Disease Organization

SCHOLARLY PAPERS

1

DOWNLOADS

170

TOTAL CITATIONS

0

Scholarly Papers (1)

Safety and Immunogenicity of Covac-2, a Sepivac Swe™ Adjuvanted Sars-Cov-2 Recombinant Protein Vaccine in Healthy Adults; a Randomized Controlled First-in-Human Dose-Escalation Trial

Number of pages: 28 Posted: 21 Aug 2024
University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Canadian Center for Vaccinology, Dalhousie University, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Vaccine Formulation Institute (VFI), Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan, Dalhousie University, Dalhousie University and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 119 (602,987)

Abstract:

Loading...

COVID-19 vaccine, protein subunit, Sepivac SWE adjuvant, immunogenicity, vaccine, clinical trial, Phase 1

Safety and Immunogenicity of Covac-2, a Sepivac Swe™ Adjuvanted Sars-Cov-2 Recombinant Protein Vaccine in Healthy Adults; a Randomized Controlled First-in-Human Dose-Escalation Trial

Number of pages: 33 Posted: 08 Aug 2025
University of Saskatchewan - Vaccine and Infectious Disease Organization, affiliation not provided to SSRN, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Canadian Center for Vaccinology, Dalhousie University, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Nexelis/Q2 Solutions, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan, Dalhousie University, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 51 (1,072,374)

Abstract:

Loading...

COVID-19 vaccine, protein subunit, SWE adjuvant, immunogenicity, vaccine, clinical trial, Phase 1